Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer

Journal:
The New England Journal of Medicine
Published:
DOI:
10.1056/nejmoa2502931
Affiliations:
23
Authors:
27
Go to article
Institutions Authors Share
Bristol-Myers Squibb, United States of America (USA)
6.000000
 0.22
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, United States of America (USA)
2.000000
 0.07
State Key Laboratory of Molecular Oncology, China
1.000000
 0.04
University of Occupational and Environmental Health (UOEH), Japan
1.000000
 0.04
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)
1.000000
 0.04
St. James's Hospital (SJH), TCD, Ireland
1.000000
 0.04
Aberdeen Royal Infirmary, NHS Grampian, United Kingdom (UK)
1.000000
 0.04
Instituto Alexander Fleming, Argentina
1.000000
 0.04
Tianjin Medical University Cancer Institute and Hospital, TMU, China
1.000000
 0.04
Charleston Oncology, United States of America (USA)
1.000000
 0.04
McGill University Health Centre (MUHC), Canada
1.000000
 0.04
Kanagawa Cancer Center, Japan
1.000000
 0.04
Johns Hopkins Medicine (JHM), JHU, United States of America (USA)
1.000000
 0.04
Institut du Thorax Curie-Montsouris, France
1.000000
 0.04
Brigham and Women's Hospital (BWH), United States of America (USA)
1.000000
 0.04
Kindai University, Japan
1.000000
 0.04
Hospital of the University of Montreal (CHUM), Canada
1.000000
 0.04
Shanghai Chest Hospital, SJTU, China
1.000000
 0.04
Hospital Universitario Puerta de Hierro Majadahonda, UAM, Spain
1.000000
 0.04
Vall d'Hebron University Hospital (HUVH), ICS, Spain
0.500000
 0.02
Autonomous University of Barcelona (UAB), Spain
0.500000
 0.02
The Oncology Institute "Prof. Dr. Ion Chiricuta" (IOCN), Romania
0.500000
 0.02
Iuliu Hațieganu University of Medicine and Pharmacy (UMF Cluj), Romania
0.500000
 0.02
Interested in Oncology and Carcinogenesis?